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More than 340 experts in agriculture, medicine, biotechnology, business,
consumer health and policy from thirty-seven states and five countries
convened at the Foods for Health conference in Minneapolis May 19–21, 2002.
This annual conference marked a significant effort to expand the circle of
discussion on agricultural biotechnology to include nutrition and healthcare
professions. Participants explored the implications of better integrating
medicine and food production to increase the health value of foods and the
potential of therapeutics using plant-derived and technology-based enhance-
ments.
The conference was hosted by the University of Minnesota’s College of
Agricultural, Food and Environmental Sciences and its Academic Health
Center. Co-hosts Charles C. Muscoplat, Vice President and Dean of the College
of Agricultural, Food and Environmental Sciences, and Frank Cerra, Senior
Vice President for Health Sciences, highlighted integrated efforts at the
University of Minnesota, including their partnership in the university’s
interdisciplinary Center for Plants and Human Health.
DIET AND HEALTH: CHALLENGES AND POTENTIALS
Dual keynote addresses that described the challenges presented by diet-related
disease and the opportunities at the intersection of agriculture and medicine set
the stage for discussion at the conference. Shiriki Kumanyika, Center for
Clinical Epidemiology and Biostatistics at the University of Pennsylvania School
of Medicine, cited the increasing incidence of diet-related chronic diseases in
the United States and worldwide, and provided data on direct costs to society.
Charles Arntzen, founding director of the Arizona Biomedical Institute at
Arizona State University, described the potential for addressing diet-related
chronic disease through improvements in foods and in new therapeutics
derived from agricultural and horticultural crop plants.
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Kumanyika summarized the magnitude of the diet-related chronic disease
problem as it affects the global population as well as individuals and their
families. She noted that obesity and type-2 diabetes costs society in the United
States $50 billion per year (in 1995 dollars) in health services, loss of work, and
other factors. Coronary heart disease carries a $40 billion cost, with hyperten-
sion and osteoarthritis at about $18 billion. In 1995, 13.9 million people in the
United States had diabetes. Trends suggest that the number will increase to 21.9
million by 2025. India, the country with the highest rate of diabetes, will
increase from 19.4 million affected in 1995 to 57.2 million by 2025.
Arntzen summarized the human timeline of crop improvement and
applications of technology from the beginnings of crop domestication about
10,000 years ago to the present. He noted that early populations selected traits
to reduce toxicity, reducing or removing glycoalkaloids in potatoes, for
example. Over time, breeders selected traits that enhanced taste, nutritional
quality, color, and storage. Recent technologies, including plant-tissue cultures
and DNA transfer, allow more-specific improvement in traits. He emphasized
that the “transition point” from agriculture to medicine has been reached.
Researchers now are evaluating selection processes that could restore natural,
beneficial, chemicals in plants such as cancer-preventing antioxidants, that have
been lost through breeding over time. Arntzen concluded with a glimpse of the
future of plant-based vaccines, referencing his own work in potato, that has
resulted in three vaccines in stage-1 clinical trials: a hepatitis-B vaccine and two
diarrhea vaccines. He emphasized that the production of plant-based vaccines
will likely be more efficient and less expensive, and could be set up anywhere in
the world—meeting critical disease-prevention needs in developing countries.
Kumanyika and Arntzen were followed by thirty-eight speakers and panelists
who addressed the regulatory process, ethics and consumer demand, choice,
and health and wellness trends. Other speakers more specifically detailed
historical linkages between agriculture and medicine, botanicals as therapeu-
tics, plant-produced antibodies, edible vaccines, functional foods and
allergenicity. An additional fifty-two individuals served as facilitators and
recorders for conference participants as they discussed key issues in fifteen
concurrent workshop sessions1.
BIOTECHNOLOGY AS A TOOL
This conference discussion positioned biotechnology squarely as a tool, not as a
focal point or goal. Technology also featured in current and historical examples
of food as a vehicle to deliver essential nutrition to consumers—from the
emergence of nutrient-fortified breads of the mid-1900s to calcium-fortified
orange juice. With land grant university agronomists seated amid dieticians and
1See workshop summary article, page 26.
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public health service epidemiologists, the goal was articulated as: achieving
high-quality, enhanced foods and increased consumer understanding to help
improve nutrition. Further, enhancements could contribute to a reduced
incidence of diet-related chronic disease—with the long-term goal of disease
prevention. The tools of biotechnology could lead to cheaper, more-effective
and plentiful vaccines. They could support the development of medicinal
components in food to simultaneously treat symptoms and provide nutrition.
Biotechnology is already being used to generate pharmaceutical components in
commodity and horticultural crops, such as corn and tomatoes.
The potential of the tools of biotech were discussed throughout the
conference in terms of what ethicist Jeffrey Burkhardt, University of Florida,
described as “the promise of biotechnology.” He said that biotechnology will
provide benefits in the future only if scientific and legal successes are achieved,
if consumers accept new developments, and if benefits are actually conferred.
These developments cannot merely be a prediction; they must be a promise.
This promise must be an ethical obligation to act and achieve benefits in the
future.
Speakers collectively emphasized that the “promise of biotechnology” must
be realistically extended to all concerned: the public, growers, food companies
and health sector professionals. They also highlighted a shared responsibility
for keeping such promises— throughout the food system and including
regulators.
FOCUS ON CONSUMERS
Speakers addressing consumer interests and demands emphasized that there is,
in fact, no average consumer. Tastes, preferences, and cultural bases for food
choices vary widely. In sum, although consumers are somewhat confused by the
barrage of conflicting messages in the market place, they maintain interest in
nutrition, food, and health, and desire understandable, useable, and credible
information. In addition, it will be important for agricultural science to reorient
its traditional view of the farmer as its client. Many voiced the need to direct
research that is in step with the real client, the consumer. Specifically, Laurie
Demeritt, the Hartman Group, discussed five factors driving the trend toward
wellness among consumers:
• a generalized loss of control,
• transformative life experience,
• compressed sense of time,
• growing frustration with healthcare, and
• the aging population.
She noted that wellness lifestyle trends in the near term will include more
emphasis on the economy than on the environment, and an increased focus on
prevention as people continue to turn more to food as medicine and therapy.
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REGULATORY ASPECTS
Numerous speakers addressed the current regulatory framework, reflecting on
examples from the first generation of biotech crops—and speculating on new
guidelines that were published for public comment in September 2002 jointly
from the Food and Drug Administration (FDA) and the United States
Department of Agriculture (USDA). Gregory Jaffe, Center for Science in the
Public Interest, noted that, to date, almost all commercialized genetically
engineered crops have gone through the FDA’s voluntary consultation process,
in which safety data provided by companies are reviewed to ensure compliance
with existing laws. He advocated a mandatory FDA process for the second
generation of biotech foods (golden rice and high-lycopene tomato, for
example) as well as a revamping of USDA’s current system. Others noted that
many companies will not move aggressively in development of new vaccines or
enhanced foods until regulatory processes under discussion are clear. Speakers
underscored the important relationship of consumer choice to confidence in
the regulatory process and the validation of safety and efficacy of new products.
EMPHASIS ON STUDENTS
NABC 14 placed a renewed emphasis on engaging students in shaping
conference discussions and the future. The conference hosts awarded
scholarships to eight students from the fields of medicine, public policy, and
nutrition as well as from agricultural disciplines.
INNOVATIONS IN MINNESOTA
At the close of the conference, local hosts sponsored a special session that
highlighted innovation in agriculture, food and medicine in Minnesota. A panel
discussion on safe and healthy foods included Kati Fritz-Jung of Schwan’s Sales
Enterprises, Inc., Hershell Ball of Michael Foods, Inc., Susan Crockett of the
General Mills, Inc., Bell Institute of Health and Nutrition, and Steve Snyder of
Cargill Health and Food Technologies. A panel on developments in medicine
and health included Clarence Johnson of Bioenergy, Inc., Mark Bolander of the
Mayo Clinic, and Gregory Plotnikoff and Gary Gardner of the University of
Minnesota. Plotnikoff, associate professor of medicine, and Gardner, professor
of horticultural science, are part of the university’s interdisciplinary Center for
Plants and Human Health.
